JP2004508333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508333A5 JP2004508333A5 JP2002524503A JP2002524503A JP2004508333A5 JP 2004508333 A5 JP2004508333 A5 JP 2004508333A5 JP 2002524503 A JP2002524503 A JP 2002524503A JP 2002524503 A JP2002524503 A JP 2002524503A JP 2004508333 A5 JP2004508333 A5 JP 2004508333A5
- Authority
- JP
- Japan
- Prior art keywords
- quetiapine
- pharmaceutically acceptable
- acceptable salt
- treating
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 description 4
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 4
- 229960004431 quetiapine Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 206010058314 Dysplasia Diseases 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
Description
【特許請求の範囲】
【請求項１】 注意不足活動亢進症を治療するための医薬の製造におけるクエチアピンまたはその製薬上許容し得る塩の使用。
【請求項２】 行状異常症を治療するための医薬の製造におけるクエチアピンまたはその製薬上許容し得る塩の使用。
【請求項３】 注意不足活動亢進症または行状異常症に関連する障害を治療するための医薬の製造におけるクエチアピンまたはその製薬上許容し得る塩の使用。
【請求項４】 クエチアピンまたはその製薬上許容し得る塩を注意不足活動亢進症、行状異常症または関連する障害の治療に有用なその他の薬剤の１種または２種以上と共に投与する請求項１〜３のいずれか１項に記載の使用。
【請求項５】 その他の薬剤の１種または２種以上がアンフェタミン、メチルフェニデート、ビュープロピオン、デシプラミン、イミプラミンおよびノルトリプチリンから選択される請求項４に記載の使用。
【請求項１】 注意不足活動亢進症を治療するための医薬の製造におけるクエチアピンまたはその製薬上許容し得る塩の使用。
【請求項２】 行状異常症を治療するための医薬の製造におけるクエチアピンまたはその製薬上許容し得る塩の使用。
【請求項３】 注意不足活動亢進症または行状異常症に関連する障害を治療するための医薬の製造におけるクエチアピンまたはその製薬上許容し得る塩の使用。
【請求項４】 クエチアピンまたはその製薬上許容し得る塩を注意不足活動亢進症、行状異常症または関連する障害の治療に有用なその他の薬剤の１種または２種以上と共に投与する請求項１〜３のいずれか１項に記載の使用。
【請求項５】 その他の薬剤の１種または２種以上がアンフェタミン、メチルフェニデート、ビュープロピオン、デシプラミン、イミプラミンおよびノルトリプチリンから選択される請求項４に記載の使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0003126A SE0003126D0 (sv) | 2000-09-05 | 2000-09-05 | Method of treatment |
| PCT/SE2001/001879 WO2002020019A1 (en) | 2000-09-05 | 2001-08-31 | New use of quetiapine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508333A JP2004508333A (ja) | 2004-03-18 |
| JP2004508333A5 true JP2004508333A5 (ja) | 2008-09-04 |
Family
ID=20280890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002524503A Abandoned JP2004508333A (ja) | 2000-09-05 | 2001-08-31 | クエチアピンの新規な用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7338948B2 (ja) |
| EP (1) | EP1326616B1 (ja) |
| JP (1) | JP2004508333A (ja) |
| AT (1) | ATE291920T1 (ja) |
| AU (1) | AU2001282832A1 (ja) |
| DE (1) | DE60109799T2 (ja) |
| ES (1) | ES2238469T3 (ja) |
| HK (1) | HK1056120A1 (ja) |
| PT (1) | PT1326616E (ja) |
| SE (1) | SE0003126D0 (ja) |
| WO (1) | WO2002020019A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1838325A1 (en) * | 2005-01-07 | 2007-10-03 | AstraZeneca AB | NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS |
| US20090035370A1 (en) * | 2007-08-02 | 2009-02-05 | Drugtech Corporation | Dosage form and method of use |
| GB0822077D0 (en) * | 2008-12-03 | 2009-01-07 | Minster Res Ltd | Novel treatments |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US5605897A (en) | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| GB9611328D0 (en) | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
-
2000
- 2000-09-05 SE SE0003126A patent/SE0003126D0/xx unknown
-
2001
- 2001-08-31 ES ES01961576T patent/ES2238469T3/es not_active Expired - Lifetime
- 2001-08-31 AU AU2001282832A patent/AU2001282832A1/en not_active Abandoned
- 2001-08-31 US US10/398,307 patent/US7338948B2/en not_active Expired - Fee Related
- 2001-08-31 EP EP01961576A patent/EP1326616B1/en not_active Expired - Lifetime
- 2001-08-31 PT PT01961576T patent/PT1326616E/pt unknown
- 2001-08-31 AT AT01961576T patent/ATE291920T1/de not_active IP Right Cessation
- 2001-08-31 WO PCT/SE2001/001879 patent/WO2002020019A1/en active IP Right Grant
- 2001-08-31 JP JP2002524503A patent/JP2004508333A/ja not_active Abandoned
- 2001-08-31 DE DE60109799T patent/DE60109799T2/de not_active Expired - Fee Related
-
2003
- 2003-11-20 HK HK03108463A patent/HK1056120A1/xx not_active IP Right Cessation
-
2008
- 2008-01-10 US US11/972,350 patent/US20080108597A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2017047I1 (no) | Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt | |
| JP2003503454A5 (ja) | ||
| CN1545409A (zh) | 二苯乙烯类化合物在制备用于治疗和预防糖尿病或与逆转录病毒有关疾病的药物中用途 | |
| CA2458067A1 (en) | Use of flibanserin in the treatment of sexual disorders | |
| HK1041485A1 (en) | Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament | |
| CA2431565A1 (en) | Pharmaceutical compositions based on anticholinergics and ciclesonide | |
| IL159151A0 (en) | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments | |
| DE602005017541D1 (de) | Verfahren zur Herstellung von 1,3,4,5-tetrahydro-2H-3-Benzazepin-2-on-Derivaten und dessen Anwendung in der Herstellung von Ivabradin sowie dessen pharmazeutisch verträglichen Salze | |
| JP2002542248A5 (ja) | ||
| EP1440689A3 (en) | Treatment of neurotic disorders | |
| GB2368525B (en) | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease | |
| WO2000008007A3 (de) | Cyclopentabenzofuran-derivate und ihre verwendung | |
| NZ502495A (en) | Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome | |
| JP2004508333A5 (ja) | ||
| ZA200107143B (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders. | |
| ME01402B (me) | Postupak sinteze derivata 1.3-dihidro-2h-3-benzazepin-2-on-a i primena u sintezi ivabradina i adicionih soli farmaceutski prihvatljive kiseliine | |
| JP2002542281A5 (ja) | ||
| USD448842S1 (en) | Multi-port catheter assembly for a respiratory care system | |
| CA2396209A1 (en) | The use of mirtazapine for the treatment of sleep disorders | |
| JP2003522147A5 (ja) | ||
| JP2003501387A5 (ja) | ||
| HK1073779A1 (en) | The use of darifenacin and the salt thereof | |
| USD448843S1 (en) | Multi-port catheter assembly for a respiratory care system | |
| RU2004112422A (ru) | Роувастатин в преддеменционных состояниях | |
| WO2000048582A3 (de) | Pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der drogenabhängigkeit |